Ashland (ASH) to Release Quarterly Earnings on Tuesday

Ashland (NYSE:ASH) is expected to release its earnings data after the market closes on Tuesday, January 28th. Analysts expect Ashland to post earnings of $0.79 per share and revenue of $429,038.33 billion for the quarter. Ashland has set its FY 2025 guidance at EPS.Investors interested in registering for the company’s conference call can do so using this link.

Ashland (NYSE:ASH) last announced its earnings results on Wednesday, November 6th. The basic materials company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.28 by ($0.02). Ashland had a return on equity of 7.43% and a net margin of 7.95%. The business had revenue of $522.00 million during the quarter, compared to analyst estimates of $524.07 million. During the same period in the previous year, the firm earned $0.41 earnings per share. The firm’s revenue was up .8% compared to the same quarter last year. On average, analysts expect Ashland to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Ashland Trading Up 1.1 %

ASH stock opened at $71.54 on Tuesday. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.44 and a quick ratio of 1.33. The stock has a market capitalization of $3.37 billion, a price-to-earnings ratio of 21.35, a P/E/G ratio of 1.11 and a beta of 0.87. The business has a fifty day moving average price of $74.08 and a 200 day moving average price of $83.14. Ashland has a fifty-two week low of $68.14 and a fifty-two week high of $102.50.

Ashland Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Sunday, December 15th. Shareholders of record on Sunday, December 1st were issued a dividend of $0.405 per share. This represents a $1.62 dividend on an annualized basis and a yield of 2.26%. The ex-dividend date was Friday, November 29th. Ashland’s dividend payout ratio is currently 48.36%.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. BMO Capital Markets upped their price objective on Ashland from $83.00 to $84.00 and gave the stock a “market perform” rating in a report on Wednesday, December 11th. StockNews.com lowered Ashland from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Wells Fargo & Company lowered their price objective on Ashland from $95.00 to $90.00 and set an “overweight” rating for the company in a research report on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $102.00.

Insider Buying and Selling

In related news, VP Eric N. Boni sold 451 shares of Ashland stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $78.07, for a total transaction of $35,209.57. Following the transaction, the vice president now owns 14,182 shares of the company’s stock, valued at $1,107,188.74. This trade represents a 3.08 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Robin E. Lampkin sold 868 shares of the stock in a transaction on Friday, November 15th. The stock was sold at an average price of $77.90, for a total transaction of $67,617.20. Following the completion of the sale, the senior vice president now owns 2,883 shares in the company, valued at approximately $224,585.70. This trade represents a 23.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.02% of the stock is owned by insiders.

Ashland Company Profile

Ashland Inc provides additives and specialty ingredients in the North and Latin America, Europe, Asia Pacific, and internationally. It operates through Life Sciences, Personal Care, Specialty Additives, and Intermediates segments. The Life Sciences segment offers pharmaceutical solutions, including controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and tablet binders; nutrition solutions, such as thickeners, stabilizers, emulsifiers, and additives; and nutraceutical solutions comprising products for weight management, joint comfort, stomach and intestinal health, sports nutrition, and general wellness, as well as custom formulation, toll processing, and particle engineering solutions.